

12 month risk of opioid overdose in patients with comorbid T2DM and OUD
(Comparision between matched semaglutide vs other anti-diabetic medications groups)

Size/group	Exposure	Comparison	Cases (overall risk) (Exposure)	Cases (overall risk) (Comparison)	Risk difference (95% CI)	HR (95% CI)
2,790	semaglutide	insulin	42 (1.51%)	97 (3.48%)	−1.97% (−2.79%, −1.16%)	0.42 (0.29–0.60)
2,605	semaglutide	metformin	35 (1.34%)	76 (2.92%)	−1.57% (−2.36%, −0.79%)	0.46 (0.31–0.68)
1,751	semaglutide	DPP−4i	22 (1.26%)	57 (3.26%)	−2.00% (−2.98%, −1.02%)	0.37 (0.23–0.61)
2,361	semaglutide	SGLT2i	36 (1.53%)	61 (2.58%)	−1.06% (−1.87%, −0.25%)	0.58 (0.38–0.87)
2,128	semaglutide	SU	27 (1.27%)	54 (2.54%)	−1.27% (−2.09%, −0.45%)	0.49 (0.31–0.78)
723	semaglutide	TZD	<10 (<1.38%)	15 (2.08%)	−0.69% (−2.04%, 0.65%)	0.32 (0.12–0.89)
2,406	semaglutide	other GLP−1RAs	31 (1.29%)	55 (2.29%)	−1.00% (−1.75%, −0.25%)	0.56 (0.36–0.87)
1,186	semaglutide	Liraglutide	15 (1.27%)	33 (2.78%)	−1.52% (−2.65%, −0.39%)	0.45 (0.25–0.84)
2,204	semaglutide	Dulaglutide	27 (1.23%)	38 (1.72%)	−0.50% (−1.21%, 0.21%)	0.71 (0.43–1.15)

0.10 0.20 0.40 0.80 2.0 4.0 10.00

Hazard Ratio (HR)